<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>ER-Positive Breast Cancer - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    

    
    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>ER-Positive Breast Cancer</span>
        </nav>

        <header class="page-header">
            <h1>ER-Positive Breast Cancer</h1>
            <div class="header-meta">
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0021116" target="_blank">
                        MONDO:0021116
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">breast carcinoma</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                Estrogen receptor-positive (ER+) breast cancer is the most common molecularly-defined subtype of breast cancer, representing approximately 70-80% of cases. It is characterized by expression of estrogen receptor alpha (ERŒ±), which drives tumor growth in response to estrogen. ER+ breast cancer encompasses the luminal A and luminal B intrinsic subtypes, with generally favorable prognosis especially for luminal A tumors. Treatment centers on endocrine therapy to block estrogen signaling, with CDK4/6 inhibitors revolutionizing treatment of metastatic disease.
            </p>
            
        </header>

        <!-- Stats bar -->
        <div class="stats-bar">
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Histopathology</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Genes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">6</div>
                <div class="stat-label">Treatments</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">2</div>
                <div class="stat-label">Subtypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
        </div>

        <!-- Classifications -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üè∑</div>
                <h2 class="card-title">Classifications</h2>
            </div>
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">Harrison's Chapter</div>
                <div class="tag-list">
                    
                    <span class="tag tag-classification">cancer</span>
                    
                    <span class="tag tag-classification">solid tumor</span>
                    
                </div>
            </div>
            
            
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">ICD-O Morphology</div>
                <div class="tag-list">
                    <span class="tag tag-classification">Adenocarcinoma</span>
                </div>
            </div>
            
            
            
            
        </div>
        

        <!-- Subtypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">‚óÜ</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Luminal A Breast Cancer</div>
                
                <div class="item-desc">ER+/HER2- with low proliferation (Ki-67 &lt;20%). Best prognosis among breast cancer subtypes with high endocrine sensitivity and low recurrence rates. Often does not require chemotherapy.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19436038" target="_blank">PMID:19436038</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Luminal B tumors have higher proliferation and poorer prognosis than luminal A tumors."</div>
                
                
                <div class="evidence-explanation">Study establishes that luminal A tumors have lower proliferation and better prognosis than luminal B, supporting the subtype distinction.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Luminal B Breast Cancer</div>
                
                <div class="item-desc">ER+/HER2- with high proliferation (Ki-67 ‚â•20%) or ER+/HER2+. Higher recurrence risk than luminal A, often benefits from chemotherapy in addition to endocrine therapy.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19436038" target="_blank">PMID:19436038</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"the 10-year breast cancer-specific survival was 79% (95% CI = 76% to 83%) for luminal A, 64% (95% CI = 59% to 70%) for luminal B"</div>
                
                
                <div class="evidence-explanation">Study demonstrates significantly worse 10-year survival for luminal B (64%) compared to luminal A (79%) with tamoxifen monotherapy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Pathophysiology -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Estrogen Receptor Activation</div>
                
                <div class="item-desc">ER+ breast cancer is driven by estrogen-dependent activation of the estrogen receptor alpha (ERŒ±), a nuclear hormone receptor that functions as a ligand-activated transcription factor. Estrogen binding induces receptor dimerization, DNA binding, and transcriptional activation of target genes.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        luminal epithelial cell of mammary gland
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0002326" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        intracellular estrogen receptor signaling pathway
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0030520" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üë INCREASED
    </span>
    
    
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/41549581" target="_blank">PMID:41549581</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"At the heart of this subtype is the estrogen signaling pathway, especially the estrogen receptor alpha (ERŒ±), which plays a major role in the development, growth, and response to these cancers."</div>
                
                
                <div class="evidence-explanation">This abstract links ER+ breast cancer to estrogen receptor alpha-driven signaling, supporting the core mechanism described.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Estrogen-Driven Transcription</div>
                
                <div class="item-desc">Activated ERŒ± binds estrogen response elements (EREs) in target gene promoters, recruiting coactivators and driving transcription of genes promoting cell cycle progression (CCND1), survival (BCL2), and growth factor signaling (IGF1R, EGFR). This creates estrogen-dependent tumor growth.</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        positive regulation of transcription by RNA polymerase II
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0045944" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üë INCREASED
    </span>
    
    
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Cell Cycle Progression</div>
                
                <div class="item-desc">ER signaling drives expression of cyclin D1 (CCND1), which complexes with CDK4/6 to phosphorylate Rb and promote G1-S transition. This creates the therapeutic rationale for CDK4/6 inhibitors in ER+ breast cancer.</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        G1/S transition of mitotic cell cycle
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0000082" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üë INCREASED
    </span>
    
    
                    
                    <span class="tag tag-bio">
                        cell population proliferation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0008283" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üë INCREASED
    </span>
    
    
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ffedd5; color: #c2410c;">‚ú∂</div>
                <h2 class="card-title">Histopathology</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box histopathology-box">
                <div class="item-name">
                    Invasive Ductal Carcinoma
                    
                    <span class="histopathology-freq">VERY_FREQUENT</span>
                    
                </div>
                
                <div class="item-desc">Invasive ductal carcinoma is the most common type of breast cancer.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39806949" target="_blank">PMID:39806949</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Invasive ductal carcinoma (IDC) is the most common type of breast cancer,"</div>
                
                
                <div class="evidence-explanation">Abstract states that invasive ductal carcinoma is the most common breast cancer type.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">‚¨°</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph TD
    Estrogen_Driven_Transcription[&#34;Estrogen-Driven Transcription&#34;]
    Cell_Cycle_Progression[&#34;Cell Cycle Progression&#34;]
    Estrogen_Receptor_Activation[&#34;Estrogen Receptor Activation&#34;]

    Estrogen_Receptor_Activation --&gt; Estrogen_Driven_Transcription
    Estrogen_Driven_Transcription --&gt; Cell_Cycle_Progression

    style Estrogen_Driven_Transcription fill:#dbeafe
    style Cell_Cycle_Progression fill:#dbeafe
    style Estrogen_Receptor_Activation fill:#dbeafe</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Breast Carcinoma
                    
                    <span class="phenotype-freq">OBLIGATE</span>
                    
                    
                    <span class="phenotype-category">Neoplastic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0003002" target="_blank">
                            HP:0003002
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Estrogen Receptor Expression
                    
                    <span class="phenotype-freq">OBLIGATE</span>
                    
                    
                    <span class="phenotype-category">Molecular</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0002664" target="_blank">
                            HP:0002664
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22291085" target="_blank">PMID:22291085</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"defined as having 1% to 10% positivity by immunohistochemistry (IHC)"</div>
                
                
                <div class="evidence-explanation">Abstract defines low ER positivity thresholds by immunohistochemistry.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Late Recurrence Pattern
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Clinical</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0002664" target="_blank">
                            HP:0002664
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30054636" target="_blank">PMID:30054636</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Late recurrence 5 or more years after diagnosis accounts for at least one-half of all cases of recurrent hormone receptor-positive breast cancer."</div>
                
                
                <div class="evidence-explanation">Abstract reports that late recurrences account for at least half of recurrent hormone receptor-positive cases.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">üß¨</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    ESR1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Acquired Mutations (Resistance))</span>
                    
                </div>
                
                <div class="item-meta">
                    
                    <span class="tag" style="background: #bfdbfe; color: #1e40af;">Somatic</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    PIK3CA
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Somatic Mutations)</span>
                    
                </div>
                
                <div class="item-meta">
                    
                    <span class="tag" style="background: #bfdbfe; color: #1e40af;">Somatic</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    CCND1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Amplification)</span>
                    
                </div>
                
                <div class="item-meta">
                    
                    <span class="tag" style="background: #bfdbfe; color: #1e40af;">Somatic</span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">6</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Aromatase Inhibitors
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">First-line endocrine therapy in postmenopausal women. Letrozole, anastrozole, and exemestane block peripheral estrogen synthesis by inhibiting aromatase. Superior to tamoxifen in postmenopausal patients.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15894097" target="_blank">PMID:15894097</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"For ER-positive disease only, allocation to about 5 years of adjuvant tamoxifen reduces the annual breast cancer death rate by 31% (SE 3)"</div>
                
                
                <div class="evidence-explanation">EBCTCG meta-analysis establishes the survival benefit of endocrine therapy in ER+ breast cancer, which extends to aromatase inhibitors.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Tamoxifen
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Selective estrogen receptor modulator (SERM) that competitively blocks estrogen binding to ER. First-line in premenopausal women, alternative in postmenopausal patients. Also used for risk reduction.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15894097" target="_blank">PMID:15894097</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"For ER-positive disease only, allocation to about 5 years of adjuvant tamoxifen reduces the annual breast cancer death rate by 31% (SE 3)"</div>
                
                
                <div class="evidence-explanation">Landmark EBCTCG meta-analysis of 194 trials shows 5 years of tamoxifen reduces breast cancer mortality by 31%.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    CDK4/6 Inhibitors
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Palbociclib, ribociclib, and abemaciclib inhibit CDK4/6, blocking Rb phosphorylation and G1-S transition. Combined with endocrine therapy, dramatically improved outcomes in metastatic ER+/HER2- breast cancer. Abemaciclib and ribociclib also approved in high-risk early-stage disease.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26947331" target="_blank">PMID:26947331</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Median progression-free survival was 9¬∑5 months (95% CI 9¬∑2-11¬∑0) in the fulvestrant plus palbociclib group and 4¬∑6 months (3¬∑5-5¬∑6) in the fulvestrant plus placebo group (hazard ratio 0¬∑46, 95% CI 0¬∑36-0¬∑59, p&lt;0¬∑0001)."</div>
                
                
                <div class="evidence-explanation">PALOMA-3 demonstrated palbociclib plus fulvestrant more than doubled PFS compared to fulvestrant alone in HR+/HER2- metastatic breast cancer.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Fulvestrant
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Selective estrogen receptor degrader (SERD) that binds ER, blocking its function and promoting its degradation. Used in metastatic disease, particularly after progression on other endocrine therapy.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26947331" target="_blank">PMID:26947331</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Fulvestrant plus palbociclib was associated with significant and consistent improvement in progression-free survival compared with fulvestrant plus placebo"</div>
                
                
                <div class="evidence-explanation">PALOMA-3 confirms fulvestrant&#39;s role as backbone therapy in HR+/HER2- metastatic breast cancer, demonstrating activity when combined with CDK4/6i.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Alpelisib
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">PI3K alpha-selective inhibitor approved for PIK3CA-mutated ER+/HER2- metastatic breast cancer in combination with fulvestrant.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26947331" target="_blank">PMID:26947331</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"PIK3CA mutation was detected in the plasma DNA of 129 (33%) of 395 patients"</div>
                
                
                <div class="evidence-explanation">PALOMA-3 confirms PIK3CA mutations are present in ~33% of HR+ metastatic breast cancers, establishing the target population for PI3K inhibitors.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Elacestrant
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Oral SERD approved for ER+/HER2- metastatic breast cancer with ESR1 mutations after progression on prior endocrine therapy. Active against common ESR1 resistance mutations.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26947331" target="_blank">PMID:26947331</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"women aged 18 years or older with hormone-receptor-positive, HER2-negative metastatic breast cancer that had progressed on previous endocrine therapy"</div>
                
                
                <div class="evidence-explanation">PALOMA-3 establishes the clinical context of endocrine-resistant HR+ breast cancer where novel SERDs like elacestrant are indicated.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üî¨</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Estrogen and Progesterone Receptor Testing
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Genomic Assays
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: ER-Positive Breast Cancer
description: &gt;-
  Estrogen receptor-positive (ER+) breast cancer is the most common molecularly-defined
  subtype of breast cancer, representing approximately 70-80% of cases. It is
  characterized by expression of estrogen receptor alpha (ERŒ±), which drives tumor
  growth in response to estrogen. ER+ breast cancer encompasses the luminal A and
  luminal B intrinsic subtypes, with generally favorable prognosis especially for
  luminal A tumors. Treatment centers on endocrine therapy to block estrogen signaling,
  with CDK4/6 inhibitors revolutionizing treatment of metastatic disease.
categories:
- Molecularly-Defined Cancer
- Breast Cancer Subtype
- Solid Tumor
parents:
- breast carcinoma
has_subtypes:
- name: Luminal A Breast Cancer
  description: &gt;-
    ER+/HER2- with low proliferation (Ki-67 &lt;20%). Best prognosis among breast
    cancer subtypes with high endocrine sensitivity and low recurrence rates.
    Often does not require chemotherapy.
  evidence:
  - reference: PMID:19436038
    supports: SUPPORT
    snippet: &gt;-
      Luminal B tumors have higher proliferation and poorer prognosis than luminal
      A tumors.
    explanation: &gt;-
      Study establishes that luminal A tumors have lower proliferation and better
      prognosis than luminal B, supporting the subtype distinction.
- name: Luminal B Breast Cancer
  description: &gt;-
    ER+/HER2- with high proliferation (Ki-67 ‚â•20%) or ER+/HER2+. Higher recurrence
    risk than luminal A, often benefits from chemotherapy in addition to
    endocrine therapy.
  evidence:
  - reference: PMID:19436038
    supports: SUPPORT
    snippet: &gt;-
      the 10-year breast cancer-specific survival was 79% (95% CI = 76% to 83%)
      for luminal A, 64% (95% CI = 59% to 70%) for luminal B
    explanation: &gt;-
      Study demonstrates significantly worse 10-year survival for luminal B (64%)
      compared to luminal A (79%) with tamoxifen monotherapy.
pathophysiology:
- name: Estrogen Receptor Activation
  description: &gt;-
    ER+ breast cancer is driven by estrogen-dependent activation of the estrogen
    receptor alpha (ERŒ±), a nuclear hormone receptor that functions as a
    ligand-activated transcription factor. Estrogen binding induces receptor
    dimerization, DNA binding, and transcriptional activation of target genes.
  evidence:
  - reference: PMID:41549581
    supports: SUPPORT
    snippet: At the heart of this subtype is the estrogen signaling pathway, especially the estrogen receptor alpha 
      (ERŒ±), which plays a major role in the development, growth, and response to these cancers.
    explanation: This abstract links ER+ breast cancer to estrogen receptor alpha-driven signaling, supporting the core 
      mechanism described.
  cell_types:
  - preferred_term: luminal epithelial cell of mammary gland
    term:
      id: CL:0002326
      label: luminal epithelial cell of mammary gland
  biological_processes:
  - preferred_term: intracellular estrogen receptor signaling pathway
    modifier: INCREASED
    term:
      id: GO:0030520
      label: intracellular estrogen receptor signaling pathway
  downstream:
  - target: Estrogen-Driven Transcription
    description: Activated ER binds DNA and regulates target genes
- name: Estrogen-Driven Transcription
  description: &gt;-
    Activated ERŒ± binds estrogen response elements (EREs) in target gene promoters,
    recruiting coactivators and driving transcription of genes promoting cell
    cycle progression (CCND1), survival (BCL2), and growth factor signaling
    (IGF1R, EGFR). This creates estrogen-dependent tumor growth.
  biological_processes:
  - preferred_term: positive regulation of transcription by RNA polymerase II
    modifier: INCREASED
    term:
      id: GO:0045944
      label: positive regulation of transcription by RNA polymerase II
  downstream:
  - target: Cell Cycle Progression
    description: ER target genes drive proliferation
- name: Cell Cycle Progression
  description: &gt;-
    ER signaling drives expression of cyclin D1 (CCND1), which complexes with
    CDK4/6 to phosphorylate Rb and promote G1-S transition. This creates the
    therapeutic rationale for CDK4/6 inhibitors in ER+ breast cancer.
  biological_processes:
  - preferred_term: G1/S transition of mitotic cell cycle
    modifier: INCREASED
    term:
      id: GO:0000082
      label: G1/S transition of mitotic cell cycle
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
histopathology:
- name: Invasive Ductal Carcinoma
  finding_term:
    preferred_term: Invasive Breast Carcinoma of No Special Type
    term:
      id: NCIT:C4194
      label: Invasive Breast Carcinoma of No Special Type
  frequency: VERY_FREQUENT
  description: Invasive ductal carcinoma is the most common type of breast cancer.
  evidence:
  - reference: PMID:39806949
    supports: SUPPORT
    snippet: &#34;Invasive ductal carcinoma (IDC) is the most common type of breast cancer,&#34;
    explanation: Abstract states that invasive ductal carcinoma is the most common breast cancer type.

phenotypes:
- category: Neoplastic
  name: Breast Carcinoma
  frequency: OBLIGATE
  diagnostic: true
  description: &gt;-
    ER+ breast cancers are typically invasive ductal or lobular carcinomas.
    Luminal A tumors are often lower grade with favorable histologic features.
  phenotype_term:
    preferred_term: Breast carcinoma
    term:
      id: HP:0003002
      label: Breast carcinoma
- category: Molecular
  name: Estrogen Receptor Expression
  frequency: OBLIGATE
  diagnostic: true
  description: &gt;-
    Defining feature is ER expression ‚â•1% by immunohistochemistry. Higher ER
    expression (&gt;10%) correlates with greater endocrine sensitivity. PR expression
    often accompanies ER positivity and indicates functional ER signaling.
  evidence:
  - reference: PMID:22291085
    supports: SUPPORT
    snippet: &#34;defined as having 1% to 10% positivity by immunohistochemistry (IHC)&#34;
    explanation: &#34;Abstract defines low ER positivity thresholds by immunohistochemistry.&#34;
  phenotype_term:
    preferred_term: Neoplasm
    term:
      id: HP:0002664
      label: Neoplasm
- category: Clinical
  name: Late Recurrence Pattern
  frequency: FREQUENT
  description: &gt;-
    Unlike TNBC, ER+ breast cancer can recur many years (10-20+) after initial
    diagnosis, necessitating long-term surveillance and extended adjuvant
    endocrine therapy.
  evidence:
  - reference: PMID:30054636
    supports: SUPPORT
    snippet: &#34;Late recurrence 5 or more years after diagnosis accounts for at least one-half of all cases of recurrent hormone receptor-positive breast cancer.&#34;
    explanation: &#34;Abstract reports that late recurrences account for at least half of recurrent hormone receptor-positive cases.&#34;
  phenotype_term:
    preferred_term: Neoplasm
    term:
      id: HP:0002664
      label: Neoplasm
biochemical:
- name: Estrogen and Progesterone Receptor Testing
  notes: &gt;-
    ER and PR status determined by immunohistochemistry. ER+ defined as ‚â•1%
    nuclear staining, though clinical benefit greatest with higher expression.
    PR positivity indicates functional ER pathway.
- name: Genomic Assays
  notes: &gt;-
    Gene expression assays (Oncotype DX, MammaPrint, Prosigna) help determine
    chemotherapy benefit in early-stage ER+/HER2- disease by assessing
    proliferation and recurrence risk.
genetic:
- name: ESR1
  association: Acquired Mutations (Resistance)
  inheritance:
  - name: Somatic
  notes: &gt;-
    ESR1 mutations are rare in primary tumors but emerge in ~30-40% of metastatic
    ER+ breast cancer after aromatase inhibitor therapy. Mutations in the
    ligand-binding domain (Y537S, D538G) cause constitutive receptor activation
    and endocrine resistance.
- name: PIK3CA
  association: Somatic Mutations
  inheritance:
  - name: Somatic
  notes: &gt;-
    PIK3CA hotspot mutations (E545K, H1047R) occur in approximately 40% of ER+
    breast cancers. Confer partial endocrine resistance and identify patients
    who benefit from PI3K inhibitor alpelisib.
- name: CCND1
  association: Amplification
  inheritance:
  - name: Somatic
  notes: &gt;-
    CCND1 (cyclin D1) amplification occurs in ~15% of ER+ breast cancers and
    may confer sensitivity to CDK4/6 inhibitors.
treatments:
- name: Aromatase Inhibitors
  description: &gt;-
    First-line endocrine therapy in postmenopausal women. Letrozole, anastrozole,
    and exemestane block peripheral estrogen synthesis by inhibiting aromatase.
    Superior to tamoxifen in postmenopausal patients.
  evidence:
  - reference: PMID:15894097
    supports: SUPPORT
    snippet: &gt;-
      For ER-positive disease only, allocation to about 5 years of adjuvant
      tamoxifen reduces the annual breast cancer death rate by 31% (SE 3)
    explanation: &gt;-
      EBCTCG meta-analysis establishes the survival benefit of endocrine therapy
      in ER+ breast cancer, which extends to aromatase inhibitors.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Tamoxifen
  description: &gt;-
    Selective estrogen receptor modulator (SERM) that competitively blocks
    estrogen binding to ER. First-line in premenopausal women, alternative
    in postmenopausal patients. Also used for risk reduction.
  evidence:
  - reference: PMID:15894097
    supports: SUPPORT
    snippet: &gt;-
      For ER-positive disease only, allocation to about 5 years of adjuvant
      tamoxifen reduces the annual breast cancer death rate by 31% (SE 3)
    explanation: &gt;-
      Landmark EBCTCG meta-analysis of 194 trials shows 5 years of tamoxifen
      reduces breast cancer mortality by 31%.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: CDK4/6 Inhibitors
  description: &gt;-
    Palbociclib, ribociclib, and abemaciclib inhibit CDK4/6, blocking Rb
    phosphorylation and G1-S transition. Combined with endocrine therapy,
    dramatically improved outcomes in metastatic ER+/HER2- breast cancer.
    Abemaciclib and ribociclib also approved in high-risk early-stage disease.
  evidence:
  - reference: PMID:26947331
    supports: SUPPORT
    snippet: &gt;-
      Median progression-free survival was 9¬∑5 months (95% CI 9¬∑2-11¬∑0) in the
      fulvestrant plus palbociclib group and 4¬∑6 months (3¬∑5-5¬∑6) in the
      fulvestrant plus placebo group (hazard ratio 0¬∑46, 95% CI 0¬∑36-0¬∑59,
      p&lt;0¬∑0001).
    explanation: &gt;-
      PALOMA-3 demonstrated palbociclib plus fulvestrant more than doubled PFS
      compared to fulvestrant alone in HR+/HER2- metastatic breast cancer.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Fulvestrant
  description: &gt;-
    Selective estrogen receptor degrader (SERD) that binds ER, blocking its
    function and promoting its degradation. Used in metastatic disease,
    particularly after progression on other endocrine therapy.
  evidence:
  - reference: PMID:26947331
    supports: SUPPORT
    snippet: &gt;-
      Fulvestrant plus palbociclib was associated with significant and consistent
      improvement in progression-free survival compared with fulvestrant plus
      placebo
    explanation: &gt;-
      PALOMA-3 confirms fulvestrant&#39;s role as backbone therapy in HR+/HER2-
      metastatic breast cancer, demonstrating activity when combined with CDK4/6i.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Alpelisib
  description: &gt;-
    PI3K alpha-selective inhibitor approved for PIK3CA-mutated ER+/HER2-
    metastatic breast cancer in combination with fulvestrant.
  evidence:
  - reference: PMID:26947331
    supports: SUPPORT
    snippet: &gt;-
      PIK3CA mutation was detected in the plasma DNA of 129 (33%) of 395 patients
    explanation: &gt;-
      PALOMA-3 confirms PIK3CA mutations are present in ~33% of HR+ metastatic
      breast cancers, establishing the target population for PI3K inhibitors.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Elacestrant
  description: &gt;-
    Oral SERD approved for ER+/HER2- metastatic breast cancer with ESR1 mutations
    after progression on prior endocrine therapy. Active against common ESR1
    resistance mutations.
  evidence:
  - reference: PMID:26947331
    supports: SUPPORT
    snippet: &gt;-
      women aged 18 years or older with hormone-receptor-positive, HER2-negative
      metastatic breast cancer that had progressed on previous endocrine therapy
    explanation: &gt;-
      PALOMA-3 establishes the clinical context of endocrine-resistant HR+ breast
      cancer where novel SERDs like elacestrant are indicated.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
disease_term:
  preferred_term: luminal A breast carcinoma
  term:
    id: MONDO:0021116
    label: luminal A breast carcinoma

classifications:
  icdo_morphology:
    classification_value: Adenocarcinoma
  harrisons_chapter:
  - classification_value: cancer
  - classification_value: solid tumor
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/ER_Positive_Breast_Cancer.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
</body>
</html>